European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (eortc) [and] European Association for Cancer Research (eacr)
Overview
The European Journal of Cancer is the official journal for the European Organization for Research and Treatment of Cancer (EORTC) and the European Association for Cancer Research (EACR). It publishes high-quality research articles, reviews, and commentaries on all aspects of cancer research and treatment, with a focus on advancing knowledge and improving patient outcomes in Europe and beyond.
Details
Details
Abbr.
Eur J Cancer
Start
1990
End
Continuing
Frequency
Eighteen no. a year, 2000-
p-ISSN
0959-8049
e-ISSN
1879-0852
Country
United Kingdom
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 392
245
SJR / Ranks: 825
2501
CiteScore / Ranks: 1136
11.10
JIF / Ranks: 623
8.4
Recent Articles
11.
Villacampa G, Eminowicz G, Navarro V, Carita L, Garcia-Illescas D, Oaknin A, et al.
Eur J Cancer
. 2025 Mar;
220:115329.
PMID: 40031426
Background: Several first-line therapeutic strategies have been evaluated alongside platinum-based chemotherapy in advanced or recurrent endometrial cancer (a/rEC). However, the optimal approach remains unclear. Methods: A systematic review was conducted...
12.
Seyringer S, Pilz M, Jansen F, Buttner M, King M, Norman R, et al.
Eur J Cancer
. 2025 Mar;
219:115330.
PMID: 40024875
No abstract available.
13.
Lancaster H, Walstra A, Myers K, Avila R, Gratama J, Heuvelmans M, et al.
Eur J Cancer
. 2025 Mar;
220:115323.
PMID: 40022837
Reduction in lung cancer mortality is achievable through low dose computed tomography (LDCT) screening in high-risk individuals. Many countries are progressing from local LDCT screening studies to national screening programs....
14.
Lancaster H, Jiang B, Davies M, Gratama J, Silva M, Yi J, et al.
Eur J Cancer
. 2025 Mar;
220:115324.
PMID: 40022836
Purpose: Artificial intelligence (AI) could reduce lung cancer screening computer tomography (CT)-reading workload if used as a first-reader, ruling-out negative CT-scans at baseline. Evidence is lacking to support AI performance...
15.
Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial
Hasegawa K, Nishio S, Yamamoto K, Fujiwara H, Itagaki H, Nagai T, et al.
Eur J Cancer
. 2025 Feb;
219:115304.
PMID: 40010135
Aim: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LACC), but recurrence rates remain high. This multicenter phase-3 randomized trial (GOTIC-002) evaluated the efficacy of low-dose...
16.
Vergote I, Copeland L, Van Gorp T, Laenen A, Scambia G, Thaker P, et al.
Eur J Cancer
. 2025 Feb;
219:115306.
PMID: 40010134
Purpose: Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell viability and tumor progression. The pivotal, phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study evaluated efficacy and safety of...
17.
Ishida H, Sunakawa Y, Kodera Y, Yoshida K, Kochi M, Kakeji Y, et al.
Eur J Cancer
. 2025 Feb;
219:115322.
PMID: 39999670
Background: As adjuvant chemotherapy for stage III gastric cancer, the phase III (JACCRO GC-07) trial showed that docetaxel plus S-1 (DS) was superior to S-1 in terms of recurrence-free and...
18.
Cortiula F, Kutiel T, Hsu M, Hendriks L, Nassar A, Moskovitz M, et al.
Eur J Cancer
. 2025 Feb;
219:115302.
PMID: 39987799
Introduction: The current standard of care for fit patients with unresectable stage III NSCLC involves concurrent chemoradiation (CRT) followed by durvalumab. Disease recurrence occurs in approximately 2/3 of patients, often...
19.
Griguolo G, Bottosso M, Crema A, Giarratano T, Miglietta F, Bonomi G, et al.
Eur J Cancer
. 2025 Feb;
219:115321.
PMID: 39987798
Background: Interest in metastatic solid tumors patients achieving exceptionally durable responses to systemic treatment is progressively increasing; however, available evidence still remains limited. This study characterizes patients with metastatic breast...
20.
Steger K, Fiegl H, Feroz B, Leitner K, Marth C, Hackl H, et al.
Eur J Cancer
. 2025 Feb;
219:115320.
PMID: 39986022
Purpose: To explore why in large phase III randomized clinical trials TP53-mutated (TP53mut) endometrial cancer (EC) was the only tumor showing survival benefit to immune checkpoint inhibitors (ICIs) added to...